{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013188","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.856592+00:00","generated_at":"2026-06-24T00:57:26.503831+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MeiraGTx Q2 net loss $34M; positive XLRP gene therapy data; extends cash runway to Q4 2024","bullets":["Net loss of $34.0M ($0.76/share) vs $20.1M ($0.46) in Q2 2021; license revenue up to $10.8M.","Positive Phase 1/2 data for botaretigene sparoparvovec (AAV-RPGR) shows vision improvements in XLRP; Phase 3 Lumeos enrolling.","Secured up to $100M senior secured financing from Perceptive secured by manufacturing facilities; $75M received at close.","Cash and equivalents $72.1M at June 30 plus $15.9M Janssen receivable; cash runway to Q4 2024.","R&D expenses increased to $24.0M from $15.2M due to manufacturing and clinical costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013188","json":"https://secwatch.observer/filing/0001558370-22-013188.json","markdown":"https://secwatch.observer/filing/0001558370-22-013188.md","text":"https://secwatch.observer/filing/0001558370-22-013188.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022013188/0001558370-22-013188-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837022013188/mgtx-20220811x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:57:26.503831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}